1 active not recruiting, 1 terminated. 2 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Active not recruiting 1, Terminated 1 |
| Phase 3 | 1 | Active not recruiting 1 |
Follow Prolacta Bioscience: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study To Evaluate The Safety And Efficacy of PBCLN-010 In Combination With PBCLN-014 in Participants Receiving Allogeneic Hematopoietic Cell Transplantation B. infantis (PBCLN-014) and Human Milk Oligosaccharides (HMO) (PBCLN-010) - Hematologic Malignancy | Phase 2 | Terminated | Prolacta Bioscience | 46 | 2023-09-18 | 2024-08-19 |
| Human Milk Fortification in Extremely Preterm Infants H2MF, Bovine milk-based fortifier - Necrotizing Enterocolitis, Sepsis | Phase 2 / Phase 3 | Active not recruiting | Thomas Abrahamsson, MD, PhD | 229 | 2019-02-01 | 2024-07-23 |
Enterocolitis, Necrotizing (1) · Hematologic Neoplasms (1) · Sepsis (1)
Health Maintenance Organizations (1)
Sweden (1) · United States (1)
Thomas R Abrahamsson, MD, PhD (1)